Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance

• Published in: Diagnostic Microbiology and Infectious Disease
• Main Author: Selim H.M.R.M.; Gomaa F.A.M.; Alshahrani M.Y.; Kamel N.A.; Aboshanab K.M.; Elsayed K.M.
• Format: Article
• Language: English
• Published: Elsevier Inc. 2024
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85206250226&doi=10.1016%2fj.diagmicrobio.2024.116558&partnerID=40&md5=6b95db5a0108323f9dc67fc28b75b7d0
• ISSN: 7328893
• DOI: 10.1016/j.diagmicrobio.2024.116558

This study aimed to evaluate the antimicrobial susceptibility and combination of a beta-blocker, labetalol (LAB) and meropenem (MEM) on Carbapenem-resistant (CR) A. baumannii clinical isolates. A total of 43 CR- A. baumannii were isolated of which 37 (86.6 %) and 28 (65 %) exhibited MDR and XDR phenotypes, respectively. Colistin and doxycycline still retain their activities in 93.1 % and 72.1 % of the isolates, respectively. Combining MEM with LAB at 0.25 mg /mL, decreased MIC values in 91.4 % (32/35) however, at 0.5 mg /mL, it decreased MIC value and restored susceptibility to MEM in 100 % and 91.4 % of the tested isolates, respectively. A novel transferable plasmid pAcbGIM3 harboring aph-3′, blaoxa-58, blaGIM3 and blaCTX-M3 and eight mobile genetic elements were successfully isolated from a pan-drug resistant (PDR) isolate. In conclusion, LAB-MEM is a promising combination and should be clinically examined. This is the first report of a transmissible plasmid harboring blaGIM3 gene in Egypt. © 2024 Elsevier Inc.